CareDx, Inc. CDNA
80.77 USD -3.65 (-4.32%)
At closeNov 10, 2026, 7:10 PM EST
82.00 +1.23 +1.52%
After hours · Nov 10, 7:10 PM ET
79.27 Day range 84.50
15.15 52-week range 90.87
- YTD
- +328.72%
- 1 year
- +383.65%
News
businesswire.com CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of…
zacks.com CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
seekingalpha.com Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review The top contributors to the Portfolio's relative performance in the quarter were Kodiak Sciences, Flotek Industries, and Hyperliquid Strategies. The most significant detractors from the Portfolio's…
seekingalpha.com Baron Discovery Fund Q3 2026 Portfolio Activity During the quarter, we initiated a position in Jersey Mike's Subs Inc., a franchisor of fast casual, submarine-style sandwich restaurants. We participated in the IPO of Lyntris Inc., a fast-growing…
zacks.com CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth CDNA raises its 2026 revenue and profit outlook as transplant testing demand and NavDx growth accelerate, with new molecular diagnostics set for 2027 launches.
businesswire.com CareDx Announces Third KOAR Analysis Published in Transplantation BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication…
fool.com Why CareDx Stock Soared Today CareDx is a leader in the fast-growing field of medical diagnostics. The company is working to bring its non-invasive tests to new markets.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
seekingalpha.com CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
benzinga.com Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
marketbeat.com What CareDx (CDNA) Said on Its Q3 Earnings Call CareDx NASDAQ: CDNA reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July…
zacks.com CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates CareDx (CDNA) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.28 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
benzinga.com CareDx Raises FY2026 Sales Guidance from $490.000M-$500.000M to $520.000M-$530.000M vs $489.692M Est CareDx (NASDAQ:CDNA) raises FY2026 sales outlook from $490.000 million-$500.000 million to $520.000 million-$530.000 million vs $489.692 million estimate.
benzinga.com CareDx Q3 Adj. EPS $0.70 Beats $0.25 Estimate, Sales $139.362M Beat $120.608M Estimate CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.25 by 180 percent. This is a 150 percent increase over earnings of $0.28 per share…
businesswire.com CareDx Announces Third Quarter 2026 Financial Results BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results…
zacks.com CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus CareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.
businesswire.com CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring…- benzinga.com Canaccord Genuity Maintains Buy on CareDx, Raises Price Target to $80 Canaccord Genuity analyst Kyle Mikson maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $65 to $80.
gurufocus.com CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overvalued On October 16, 2026, CareDx Inc (CDNA) shares fell 4.0% to $64.00, reflecting a volatile performance over the past year, with a 52-week high of $72.51 and a low
businesswire.com CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026 BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report…
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
defenseworld.net Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA) CareDx (NASDAQ: CDNA - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
zacks.com CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the…
benzinga.com Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save…
benzinga.com Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
zacks.com 5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential Five stocks stand out for high efficiency, with strong receivables, asset, inventory and operating margin metrics.
defenseworld.net CareDx (NASDAQ:CDNA) Hits New 1-Year High – Time to Buy? CareDx, Inc. (NASDAQ: CDNA - Get Free Report)'s share price reached a new 52-week high on Monday. The stock traded as high as $55.21 and last traded at $53.7380, with a volume of 1203 shares. The…
benzinga.com Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65 Canaccord Genuity analyst Kyle Mikson initiates coverage on CareDx (NASDAQ:CDNA) with a Buy rating and announces Price Target of $65.
benzinga.com CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
benzinga.com HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $46 Price Target HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral and maintains $46 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
benzinga.com CareDx Q2 Adj. EPS $0.37 Beats $0.23 Estimate, Sales $131.948M Beat $114.044M Estimate CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.23 by 60.87 percent. This is a 270 percent increase over earnings of $0.10 per…- benzinga.com CareDx Raises FY2026 Sales Guidance from $447.000M-$465.000M to $490.000M-$500.000M vs $455.924M Est CareDx (NASDAQ:CDNA) raises FY2026 sales outlook from $447.000 million-$465.000 million to $490.000 million-$500.000 million vs $455.924 million estimate.
benzinga.com Why Is CareDx Stock Skyrocketing Thursday? CareDx ($CDNA) shares surge 28% as Medicare finalizes continued coverage for its kidney, heart, and lung transplant tests.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's regular session. The company's market cap stands at $7.6 million. Agape ATP (NASDAQ:ATPC) shares moved…
benzinga.com Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, stock jumps 12.1%. Other big gainers include ATAI, MAN, DSGR, CDNA, MAAS, HELP, RHI, SMG, FWRD, UNH,…- benzinga.com CareDx Finalizes Medicare Local Coverage Determination Procedure Regarding Molecular Testing For Solid Organ Allograft Rejection CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage…
- benzinga.com CareDx Completes Sale Of Its Lab Products Operations To Eurobio Scientific For $171.2M CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value…
benzinga.com CareDx's 2021 Qui Tam Action Dismissed; No Monetary Payment Associated With Dismissal CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value…
benzinga.com CareDx Files For Mixed Shelf; Size Not Disclosed CareDx, Inc.Common StockPreferred StockDebt SecuritiesWarrantsSubscription RightsUnitsWe may offer and sell, from time to time in one or more offerings, shares of our common stock or preferred…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com CareDx Strikes Agreement To Acquire Naveris For $160M Upfront Payment, $100M In Future Milestones CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value…- benzinga.com CareDx Raises FY2026 Sales Guidance from $420.000M-$444.000M to $447.000M-$465.000M vs $436.665M Est CareDx (NASDAQ:CDNA) raises FY2026 sales outlook from $420.000 million-$444.000 million to $447.000 million-$465.000 million vs $436.665 million estimate.
- benzinga.com CareDx Q1 Adj. EPS $0.34 Beats $0.13 Estimate, Sales $117.700M Beat $104.034M Estimate CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.13 by 161.54 percent. This is a 277.78 percent increase over earnings of $0.09 per…
benzinga.com Earnings Scheduled For April 28, 2026 - benzinga.com CareDx Launches New Test That Matches Organ Donors and Patients in Under 3 Hours, Unveils AlloSeq Nano With 45-Minute Prep and Faster, More Accurate Transplant Matching CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value…